S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
NASDAQ:DTIL

Precision BioSciences Stock Forecast, Price & News

$12.65
+0.02 (+0.16 %)
(As of 09/27/2021 10:08 AM ET)
Add
Compare
Today's Range
$12.41
$12.76
50-Day Range
$9.18
$14.15
52-Week Range
$5.85
$16.60
Volume687 shs
Average Volume725,139 shs
Market Capitalization$753.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
30 days | 90 days | 365 days | Advanced Chart
Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Precision BioSciences logo

About Precision BioSciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

613th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

96th out of 195 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

Is Precision BioSciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Precision BioSciences
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings results on Wednesday, August, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.80. The business earned $68.81 million during the quarter, compared to analyst estimates of $22.74 million. Precision BioSciences had a negative net margin of 45.88% and a negative trailing twelve-month return on equity of 69.50%.
View Precision BioSciences' earnings history
.

How has Precision BioSciences' stock price been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DTIL stock has increased by 94.6% and is now trading at $12.63.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DTIL?

4 brokers have issued 1-year price targets for Precision BioSciences' stock. Their forecasts range from $14.00 to $27.00. On average, they anticipate Precision BioSciences' share price to reach $22.33 in the next year. This suggests a possible upside of 76.8% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Matthew R. Kane, President, Chief Executive Officer & Director (LinkedIn Profile)
  • John Alexander Kelly, Chief Financial & Corporate Affairs Officer
  • Jeff Smith, Chief Technology Officer
  • Derek N. Jantz, Director & Chief Scientific Officer
  • Sinu Bhandaru, Senior Director-Operations & IT

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences CEO Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among Precision BioSciences' employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.80%), Vanguard Group Inc. (4.86%), State Street Corp (4.85%), ArrowMark Colorado Holdings LLC (4.12%), Geode Capital Management LLC (1.36%) and Morgan Stanley (1.32%). Company insiders that own Precision BioSciences stock include Christopher Heery, David S Thomson, David S Thomson, Derek Jantz, Matthew R Kane, Matthew R Kane and Vince Craig Hopkin.
View institutional ownership trends for Precision BioSciences
.

Which major investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, BlackRock Inc., Rafferty Asset Management LLC, Citigroup Inc., Laurion Capital Management LP, Bank of America Corp DE, and CHI Advisors LLC. Company insiders that have sold Precision BioSciences company stock in the last year include David S Thomson, Derek Jantz, Matthew R Kane, and Vince Craig Hopkin.
View insider buying and selling activity for Precision BioSciences
or view top insider-selling stocks.

Which major investors are buying Precision BioSciences stock?

DTIL stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Integral Health Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Goldman Sachs Group Inc., Integral Health Asset Management LLC, and Panagora Asset Management Inc..
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $12.63.

How much money does Precision BioSciences make?

Precision BioSciences has a market capitalization of $752.47 million and generates $24.28 million in revenue each year. The company earns $-109,010,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Precision BioSciences have?

Precision BioSciences employs 231 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

Where are Precision BioSciences' headquarters?

Precision BioSciences is headquartered at 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at (919) 314-5512 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.